Back to news

CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility

PR Newswire•20/11/2026•08:00 ET
2

Key Highlights

  • ➤$6.25 million financing includes approximately $4.0 million gross cash proceeds
  • ➤Debt reduced $5.25 million to $12.25 million, saving approximately $0.7 million interest
  • ➤Maturity extended one year to July 1, 2028
  • ➤Interest-only payments extended through March 31, 2028
  • ➤Avenue receives 455,465 shares satisfying $2.25 million principal

CytoSorbents Announces $6.25 Million Common Stock Financing Priced At-the-Market under Nasdaq Rules and Concurrent Restructuring of Avenue Capital Credit Facility PR Newswire

* $4.0 million registered direct offering of common stock, led by existing shareholders and management * $2.25 million of Avenue debt satisfied through the issuance of common stock at the same offering price * Total debt reduced by $5.25 million, to $12.25 million, saving approximately $0.7 million in interest over 12 months * Maturity extended one year to July 1, 2028; interest-only period extended 15 months through March 31, 2028 PRINCETON, N.J., Nov. 20, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO, the "Company"), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced a $6.25 million common stock financing.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in